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Objective: The aim of this study was to investigate factors associated with thrombosis that may
contribute to recurrent pregnancy loss (habitual abortion), speciﬁcally differences in serum levels of
platelet-activating factor and thrombin-activatable ﬁbrinolysis inhibitor (carboxypeptidase B2) between
women with a history of recurrent miscarriage and those with no recurrent miscarriage history.
Materials and methods: A case-controlled, prospective study design was adopted to compare women
with a history of two or more ﬁrst-trimester miscarriages (n ¼ 42) with those with no history of
recurrent miscarriage (n ¼ 36). Participants were recruited from the Department of Obstetrics and Gy-
necology of Turgut Ozal University Hospital. Platelet-activating factor and thrombin-activatable ﬁbri-
nolysis inhibitor levels in serum samples were measured by an enzyme-linked immunosorbent assay.
Results: Platelet-activating factor levels were signiﬁcantly (p ¼ 0.018) higher in the recurrent miscarriage
group. There was no difference in levels of thrombin-activatable ﬁbrinolysis inhibitor expression be-
tween the groups.
Conclusion: Platelet-activating factor is signiﬁcantly higher in serum of patients with a history of
recurrent miscarriage than in those without such a history, with potential implications for placental
function and fetal growth, which could be relevant to miscarriage recurrence. Larger studies are indi-
cated to further examine these ﬁndings.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Loss of pregnancy in the ﬁrst trimester is relatively common,
occurring in 10e20% of clinically recognized pregnancies and in
many more that are not yet clinically recognized [1e3]. Recurrent
miscarriage (habitual abortion) is deﬁned by the United Kingdom's
Royal College of Obstetricians and Gynaecologists as three or moreand Gynecology, School of
er 57, Emek 06510, Ankara,
).
bstetrics & Gynecology. Publishedconsecutive pregnancy losses [1]. Risk of subsequent miscarriage is
estimated to be 30% after two pregnancy losses as opposed to 33%
after three losses [2]. This suggests that an evaluation after two
pregnancy losses is advisable inwomenwho have not had previous
live births, as recommended by the American College of Obstetri-
cians and Gynecologists [4]. The incidence of recurrent miscarriage
has been estimated at 0.5e3% among fertile couples of reproductive
age [3]. However, while there are various possible causes, in more
than 50% of cases no clear cause can be identiﬁed [1e3]. Among the
accepted etiologies are parental chromosomal abnormalities, un-
treated hypothyroidism, diabetes, antiphospholipid antibody syn-
drome, and some congenital uterine abnormalities [2,5]. Otherby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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causes, or infections. Both inherited thrombophilias and acquired
thrombophilias such as hyperhomocysteinemia, or activated pro-
tein C resistance have also been implicated [2,5].
One hypothesis put forward to explain recurrent miscarriage is
that it is the result of exaggerated hemostatic responses owing to
the existence of a prothrombotic state prior to pregnancy [6].
Normal embryonic implantation involves elements of the coagu-
lation and ﬁbrinolytic pathways. Thus, pregnancy in itself is asso-
ciated with higher levels of procoagulants, lower levels of
anticoagulants, and a reduced ﬁbrinolytic activity with an
increased risk of thrombosis [7]. A current theory suggests that
defects in hemostatic mechanisms contribute to placental micro-
thrombi and placentation defects in recurrent miscarriage [6e8].
However, the subject of whether an underlying prothrombotic state
contributes to recurrent miscarriage is controversial. Some studies
dispute this link and the use of prophylactic heparin during preg-
nancy inwomenwith idiopathic recurrent miscarriage without any
known inherited thrombophilia [9,10].
Evidence from other studies, on the other hand, supports the
idea of an underlying prothrombotic state, at least in a subgroup
of women with recurrent miscarriage. For example, increased
tissue factor activity, procoagulant phospholipids, and levels of
thrombomodulin, an activator of both protein C and thrombin-
activatable ﬁbrinolysis inhibitor (TAFI), has been shown in pa-
tients with two or more miscarriages compared with in women
with normal pregnancies or nonpregnant women [8]. Other
studies have shown increased platelet aggregation in response
to arachidonic acid [6], increased levels of procoagulant micro-
particles derived from platelets and other cell types [7,11],
increased thrombin levels or endogenous thrombin potential
[12,13], and increased clot strength and stability measured by
thromboelastography in women with unexplained recurrent
miscarriage [14].
Some of the controversies surrounding this subject are caused
by differences in techniques between studies and poor control of
some patient studies in terms of inclusion criteria and deﬁnition of
recurrent miscarriage [10]. Given the implication of platelet reac-
tivity and activation factors in thrombosis and recurrent pregnancy
loss, the authors aim to determine the levels of platelet-activating
factor (PAF) and of TAFI in women who had suffered two or more
unexplained ﬁrst-trimester miscarriages without any diagnosed
thrombotic disorder in a well-designed, case-controlled prospec-
tive study. PAF is associated with maintenance of healthy preg-
nancy [15], while TAFI is a procarboxypeptidase (carboxypeptidase
B2) involved in ﬁbrinolysis inhibition and contributes to throm-
bosis [16].
Materials and methods
This case-controlled, prospective study was carried out with
women recruited from the Department of Obstetrics and Gyne-
cology of Turgut Ozal University Hospital in Ankara/Turkey.
This study was approved by Fatih University Ethical Committee
and it complied with the Helsinki Declaration. All women provided
written informed consent prior to the start of the study.
Participants
A total of 78 nonpregnant women were recruited in this study.
Exclusion criteria included smoking and use of hormonal medica-
tion such as oral contraceptive pills. The study group consisted of 42
Caucasian patients with a history of two or more pregnancy losses
prior to 12 weeks of gestation and normal thrombophilia panel
tests. Three participants of the study group had a history ofpreeclampsia and two had chronic hypertension. The control group
consisted of 36 healthy Caucasianwomenmatched for age (Table 1)
who had no history of miscarriage or obstetric morbidity. No pa-
tient or control had any aspirin, steroid, or anticoagulant intake.
Participants were recruited a minimum of 6 months after the last
miscarriage event.Sample preparation
Venous blood samples were collected after overnight fasting
using a 21-gauge butterﬂy needle and placed in no-additive-
containing tubes. The serum fraction was obtained by centrifuga-
tion (2000g, 10 minutes, 4C) after storing the whole blood at room
temperature (approximately 10 minutes). All samples were stored
at 80C prior to assays.Measurement of PAF and TAFI levels
Enzyme-linked immunosorbent assay kits were used to mea-
sure the levels of PAF and TAFI according to the manufacturer's
instructions (USCN Life Science Inc., Houston, TX, USA). All samples
were analyzed in duplicate. Serum TAFI and PAF levels were pre-
sented as ng/mL and pg/mL, respectively.Statistical analysis
All statistical analyses were performed using the SPSS 16.0 (SPSS
Inc., Chicago, IL, USA) statistical package. Distributions were eval-
uated using one-sample KolmogoroveSmirnov test. Student t and
ManneWhitney U tests were used for testing differences between
groups. The results were expressed as mean ± standard deviation.
Spearman rho correlation test was used to indicate relationships
between variables. A probability level of p < 0.05 was considered
statistically signiﬁcant. Correlation between bodymass index (BMI)
and PAF levels was evaluated using Pearson correlation. The results
were evaluated within 95% conﬁdence interval, and p < 0.05 was
accepted as the level of signiﬁcance. Logistic regression analysis
was performed to discriminate between contributions of BMI and
PAF for recurrent abortus.Results
Table 1 shows the biochemical and clinical characteristics of the
study participants. The BMI was signiﬁcantly higher in the recur-
rent miscarriage group than in controls (p ¼ 0.019). The number of
gravidity and abortions was also higher in the study group than in
the control group (p < 0.001 for both), while the parity was higher
in the study group (p < 0.001).
With respect to the mediators tested, serum PAF levels were
signiﬁcantly higher in the recurrent miscarriage group than in the
control group (p ¼ 0.018) (Table 1). No difference was detected in
serum TAFI levels between groups (Table 1).
Given the signiﬁcantly higher BMI in the study group
compared with that in the control group (Table 1), a correlation
analysis was carried out to determine if there was any correlation
between BMI and PAF levels (Table 2). The analysis did not
indicate any correlation (p ¼ 0.829; Table 2). This indicated that
BMI and PAF levels were independent of each other. When using
BMI as a covariate in a logistic regression analysis, the association
with recurrent miscarriage group was attenuated to p ¼ 0.105 for
PAF level association and p ¼ 0.998 for BMI association. This
suggests a higher contribution of PAF than BMI to recurrent
miscarriage.
Table 1







Age 33.3 ± 7.9 32.7 ± 4.0 0.646
BMI 25.5 ± 3.5 22.8 ± 2.2 0.019
Gravidity (number of
pregnancies)
4.0 (2.0) 3.0 (1.0) <0.001
Parity (number of deliveries
at 20 wk)




2 (1) 0 (1) <0.001
PAF (pg/mL) 23,022 ± 10,978 15,809 ± 10,773 0.018
TAFI (ng/mL) 27.4 ± 2.3 26.4 ± 4.0 0.257
A p value of <0.05 was considered statistically signiﬁcant. Gravidity, parity, and
abortion reported as medians (interquartile range) for pregnancy number, delivery
number, and abortion number, respectively.
BMI ¼ body mass index; PAF ¼ platelet-activating factor; TAFI ¼ thrombin-acti-
vatable ﬁbrinolysis inhibitor.
Table 2
Analysis of correlation between PAF and BMI.
PAF BMI
PAF Pearson correlation 1 0.044
Signiﬁcance. (2-tailed) 0.829
N 62 26
BMI Pearson correlation 0.044 1
Sig. (2-tailed) 0.829
N 26 26
BMI ¼ body mass index; PAF ¼ platelet-activating factor.
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A pre-existing prothrombotic state is hypothesized to contribute
to unexplained recurrent miscarriage in at least a subgroup of
women, although the association is controversial [5e14]. In this
context, we analyzed the expression of PAF and TAFI in serum of
women with a history of two or more recurrent miscarriages
compared with womenwith no miscarriage history. We found that
levels of PAF but not TAFI were signiﬁcantly higher in women with
recurrent miscarriage.
Pregnancy in itself is a highly hypercoagulable state, making it
difﬁcult to distinguish between cause and effect when considering
the contribution of prothrombotic factors in recurrent miscarriage.
The lack of explanation for more than 50% of cases of recurrent
pregnancy makes the need to investigate and deﬁne possible un-
derlying causes all the more urgent.
PAF is a signaling phospholipid that is produced by numerous
cell types and is involved in mediation of inﬂammation and allergy
[15]. PAF is also associated with maintenance of healthy pregnancy
and has been implicated in ovulation, implantation, and parturition
in both humans and domestic animals [15,17]. It exerts its effects via
a high-afﬁnity receptor on the cell membrane of many cell types
including platelets. While no previous study, to our knowledge, has
implicated PAF in recurrent miscarriage, other studies have sug-
gested that increased PAF activity may contribute to other com-
plications of pregnancy. An elevated PAF level has been associated
with fetal growth restriction in rats [18,19] and a decline in
placental function [19]. By contrast, increased levels of PAF-acetyl
hydrolase (PAF-AH), an enzyme that degrades PAF, have been
observed in cord plasma from human fetuses with fetal growth
restriction [20]. Alterations in distribution and activity of PAF-AH
have also been observed in women with preeclampsia [21], and
increased PAF-AH has been associated with reproductive disordersin dairy cows [22]. Gestational diabetes mellitus has also been
associated with high levels of PAF-AH activity compared with
womenwith healthy pregnancies, andwithin a gestational diabetes
mellitus cohort, higher PAF-AH levels are associated with an
increased risk of metabolic syndrome [23]. The observation of
elevated levels of PAF in women with recurrent miscarriage war-
rants further analysis, especially in the context of rat studies
showing effects of elevated PAF levels on fetal growth and placental
function [18,19]. Studies should be extended to larger patient
groups incorporating sufﬁcient numbers to compare women with
two or less miscarriages with those with three or more, for
example. It would also be of interest to examine levels of PAF-AH in
these patients as PAF-AH levels are vital in maintaining the balance
between biosynthesis and degradation of PAF [15]. Increased PAF-
AH expression or alterations in distribution could represent a
compensatory mechanism aimed at controlling PAF levels.
Our study did not indicate any change in levels of TAFI inwomen
with recurrent miscarriage. TAFI is a carboxypeptidase (carboxy-
peptidase B2) with a central role in the inhibition of ﬁbrinolysis,
which has been increasingly implicated in thrombosis [16]. TAFI is
suggested to contribute to hypercoagulability in pregnancy, but its
role in recurrent miscarriage is uncertain. Some studies suggest
that it has no role [24,25], while others suggest that high levels of
TAFI are protective against recurrent miscarriage and levels of TAFI
are lower in women with recurrent miscarriage [16,26], and yet
others suggest that high TAFI levels may contribute to recurrent
miscarriage due to disordered ﬁbrinolysis [27]. Our study does not
support a role for altered TAFI levels inwomenwith a history of two
or more miscarriages. Again, studies with larger patient groups are
indicated.
One limitation of our study was that BMI was signiﬁcantly
higher in women with recurrent miscarriage. The World Health
Organization has deﬁned BMI cutoff points for classiﬁcation of in-
dividuals as underweight (<18.5 kg/m2), healthy weight
(18.5e24.9 kg/m2), overweight (25.0e29.9 kg/m2) and obese
(30.0 kg/m2) [28]. Our results indicate that the mean BMI for
women suffering recurrent miscarriage is in the overweight range,
as opposed to the control groupwhosemean BMI lies in the healthy
weight range. This is consistent with the published evidence sug-
gesting that overweight and obesity increase the risk of recurrent
miscarriage [29,30]. Overweight and/or obesity are also associated
with thrombotic complications in pregnancy such as venous
thrombosis and thromboembolism [31,32]. A recent study in mice
suggests that PAF may have an antiobesity function [33]. It remains
to be seenwhether this function is present in humans, andwhether
there could any connection between increased PAF levels and
attempted compensatory antiobesity mechanisms in overweight or
obese women with recurrent miscarriage. In our current study,
correlation analysis did not indicate any correlation between PAF
and BMI in our relatively small group of participants. However,
some BMI effects may be present, as indicated by the attenuated
signiﬁcance of PAF level association on correction for BMI. Future
studies with larger numbers of participants should focus on any
possible relationship between PAF and BMI, particularly in light of
the mice studies suggesting an antiobesity function for PAF [33].
In conclusion, we have observed signiﬁcantly increased levels of
PAF in serum samples fromwomenwho have suffered two or more
recurrent miscarriages. This could have implications for placental
function and fetal growth, and suggests that larger studies should
be carried out to further investigate the role of elevated PAF level in
recurrent miscarriage.
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